Total amount: € 0,00
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1782
Ishibashi N., Hiramatsu T., Shin’oka T., Nagatsu M., Kurosawa H.
Department of Cardiovascular Surgery Heart Institute of Japan Tokyo Women's Medical University, Tokyo, Japan
Aim. After cardiac surgery, some patients will develop cardiac failure requiring treatment with positive inotropic agents. Colforsin daropate hydrochloride is a newly synthesized water-soluble FORSKOLIN derivative that has positive inotropic effects. The aim of this study is to evaluate the usefulness of Colforsin daropate hydrochloride after cardiac surgery to correct congenital heart anomalies in pediatric patients.
Methods. Eight children who underwent surgery for congenital heart anomalies. Colforsin daropate hydrochloride was intravenously infused at a rate of 0.25 Ìg/kg/min for one hour beginning one hour after admission to intensive care unit. Hemo-dynamic parameters were determined before, immediately after, and 2 and 12 hours after its administration.
Results. After administration, the cardiac index and heart rate increased [3.5 to 4.7 l/min/m2; (p<0.05) and 126 to 150 beat/min; (p<0.01) respectively], while the systemic vascular resistance index decreased (2175 to 1126 dyne-sec-cm-5/m2; p<0.01). Pulmonary arterial pressure and pulmonary vascular resistance index decreased 15% and 40%, respectively, after the infusion, but the decreases were not statistically significant. No significant arrhythmia was recognized during the administration.
Conclusions. Colforsin daropate hydrochloride infusion was associated with a decrease in systemic vascular resistance and an increase in cardiac output after surgery for congenital heart anomalies. This agent proved useful after cardiac surgery in pediatric patients.